Skip to main content
Onconic Therapeutics Inc. logo

Onconic Therapeutics Inc. — Investor Relations & Filings

Ticker · 476060 ISIN · KR7476060009 KO Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2026-01-09 Director's Dealing
Country KR South Korea
Listing KO 476060

About Onconic Therapeutics Inc.

http://onconic.co.kr/

Onconic Therapeutics Inc., established in 2020, is a biopharmaceutical company specializing in the research and development of innovative drugs. A subsidiary of Jeil Pharmaceutical, the company focuses on creating novel treatments for cancer and gastrointestinal disorders, including gastroesophageal reflux disease. Its development strategy prioritizes therapeutics for conditions with high unmet medical needs and significant market potential. Onconic Therapeutics actively advances its pipeline of drug candidates through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (purchases and sales) of a specific executive (Shin Jong-kil) of Onconic Therapeutics. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2026-01-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by major shareholders or executives to disclose changes in their shareholdings. This falls under the category of 'Director's Dealing' (DIRS) as it reports share transactions by a major shareholder (Jeil Pharmaceutical Co., Ltd.) in the issuing company (Onconic Therapeutics).
2026-01-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서), which is a standard regulatory filing in South Korea (DART system) used to disclose insider trading activities. This corresponds to the 'Director's Dealing' category, as it details share transactions (sales and stock option exercises) by a company executive (John Kim, CEO).
2026-01-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory disclosure for insider trading or changes in share ownership by company directors/executives. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2026-01-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory disclosure for major shareholders (insiders) to report changes in their shareholdings, such as those resulting from bonus issues (무상증자). In the context of the provided categories, this falls under 'Major Shareholding Notification' (MRQ) as it details the change in ownership percentage of a major shareholder.
2025-12-24 Korean
[기재정정]영업실적등에대한전망(공정공시)
Earnings Release Classification · 95% confidence The document is a regulatory filing from Onconic Therapeutics regarding a 'Correction of Forecast of Operating Results' (공정공시). It provides updated financial projections for revenue and operating profit for the 2025 fiscal year, explaining the reasons for the revision (e.g., increased sales and milestone revenue). Since this is a formal regulatory disclosure of financial guidance and its subsequent correction, it falls under the category of general regulatory announcements that do not fit into specific report types like 10-K or IR. FY 2025
2025-12-23 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.